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TRANSPORT OF CELLS IN HYDROGELS convert the sol into gel thereby fixing the skin in the gelatin 
gel . The gelatin gel is said to provide support for the cultured 
CROSS - REFERENCE TO RELATED skin . 
APPLICATIONS WO2010 / 069589 refers to the use of a homogenous 
5 mixture of agarose and agarase for covering or enveloping 
This patent application is a national stage filing under 35 cells during cell transport . It is noted ( Example 2 ) that the 
U.S.C. 371 of International Application No. PCT / GB2012 / covering or enveloping of cells in this way did not signifi 
050612 , filed on Mar. 21 , 2012 , which claims priority to U.S. cantly affect the rate of cell proliferation . 
Provisional Application No. 61 / 454,877 , filed on Mar. 21 , The current invention , however , is based , at least in part , 
2011 ; and International Application No. PCT / GB2012 / upon the recognition that the encapsulation or entrapment of 
050612 , filed on Mar. 21 , 2012 also claims foreign priority dispersed cells within certain hydrogels not only maintains 
benefits to United Kingdom Patent Application No. the viability of the cells encapsulated or entrapped therein , 
1104711.5 , filed Mar. 21 , 2011 and United Kingdom Patent but that it actually suppresses cell division and / or differen 
Application No. 1113978.9 , filed Aug. 12 , 2011 , which are tiation within those cells at temperatures which include 
incorporated herein by reference in their entireties . ambient temperature . The recognition of this fact thus facili 
The present invention relates to hydrogels which may be tates new uses for hydrogels , including the short- and 
used to encapsulate or entrap live cells . The invention medium - term storage of cells within hydrogels to suppress 
further relates to methods for transporting live cells which cell division and / or differentiation , and the use of such 
are encapsulated or entrapped within hydrogels from a first 20 hydrogels as carriers for cells during transportation of those 
location to a second location and release of live cells upon cells , e.g. the sending of cells though the post upon request . 
reaching the second location . The invention further relates to In particular , this recognition allows the transportation of 
methods of treating a wound , disease tissue injury , e.g. an hydrogels comprising corneal cells from a donor to a recipi 
ocular injury or a damaged ocular surface in a subject using ent , and subsequent methods of treatment of ocular injuries 
a hydrogel comprising corneal stem cells . The hydrogels 25 or damaged ocular surfaces in the recipient . Hydrogels 
used in such methods may be ones which have been trans comprising other cells types may be used for other treat 
ported from a first location to a second location . ments , e.g. as a wound dressing . 
Although basic cell culture techniques have been used for In particular , the invention demonstrates enhanced 
over 100 years , the development of the biotechnology indus mechanical properties which are associated with strontium 
try and the more recent industrialisation of these processes 30 alginate gels and gels which are reinforced ( e.g. with nylon 
has produced a high demand for cell culture products . These meshes ) , and improvements in the viability of cells which are immobilised within gels whose pore size has been products are needed both for biopharmaceutical production controlled using a pore size controlling agent such as HEC . and for laboratory - based research . 
However , whilst cell culture consumables , for example , 35 ing further increased viability rates . Cells may readily be released from such gels , thus facilitat media , sera and associated reagents , may readily be trans In one aspect therefore , the invention provides a method ported at room or ambient temperatures , special conditions for transporting cells from a first location to a second 
need to be applied to the transportation of live cells in order location , the method comprising the steps : ( i ) encapsulating 
to maintain cell viability . or entrapping the cells in a hydrogel , wherein the hydrogel 
Traditionally , live cells have generally been transported 40 is in the form of a thin layer or disc ; ( ii ) transporting the 
by one of three methods : cell - containing hydrogel from the first location to the second 
( i ) Frozen , packed in dry ice . This can require up to 20 kg location , and optionally , ( iii ) releasing the cells from the 
of dry ice for long journeys . hydrogel at the second location . 
( ii ) Refrigerated . This requires specialised equipment for In a further aspect , the invention provides a method for 
refrigeration and hence increases distribution costs . 45 preparing cells for transportation from a first location to a 
( iii ) Cultures at ambient temperature . This requires short second location , the method comprising the steps : ( i ) encap 
transportation times ( i.e. of the order of minutes or sulating or entrapping the cells in a hydrogel , wherein the 
hours ) to avoid significant deterioration of the cell hydrogel is in the form of a thin layer or disc ; and ( ii ) 
cultures . packaging the cell - containing hydrogel for transportation 
It can readily be appreciated , therefore , that all three of the 50 from the first location to the second location . 
above methods have significant disadvantages . In a further aspect , the invention provides a method for 
The invention is based on the use of certain hydrogels . preparing cells for transportation from a first location to a 
Some hydrogels have previously been used for the storage of second location , the method comprising the steps : ( i ) encap 
living tissues . sulating or entrapping the cells in a hydrogel , wherein the 
For example , EP 1 266 570 A1 relates to the preservation 55 hydrogel is in the form of a thin layer or disc ; ( ii ) packaging 
of living organism tissue by coating the tissue with a the cell - containing hydrogel ; and optionally , ( iii ) dispatch 
thermo - reversible hydrogel - forming polymer . Examples of ing the cell - containing hydrogel for transportation to the 
such polymers are given as polypropylene oxide - polyethyl second location . 
ene oxide copolymers and polyethylene oxide triol poly In yet a further aspect , the invention provides a method 
mers . With regard to other polymers , EP 1 266 570 states 60 for fulfilling an order or request for cells , the method 
that agar gels and alginic acid - type gels have a gel - sol comprising the steps : ( i ) receiving an order or request for 
temperature which is too high for use with physiological cells ; ( ii ) encapsulating or entrapping the desired cells in a 
tissues and that the enzymes required for gel - sol conversion hydrogel , wherein the hydrogel is in the form of a thin layer 
of collagen gels damage living tissues . or disc ; ( iii ) dispatching the cell - containing hydrogel for 
JP 8023968A relates to the prevention of cultured skin 65 transportation to the location specified in the order or 
from being damaged by vibration or inversion by placing the request ; and optionally , ( iv ) transporting the cell - containing 
skin in a gelatin sol and then lowering the temperature to hydrogel to the location specified in the order or request . 
US 10,655,120 B2 
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In yet a further aspect , the invention provides the use of ably , the polymer is sodium alginate or calcium alginate or 
a hydrogel as a storage medium during the transportation of strontium alginate , most preferably strontium alginate . 
cells from a first to a second location , wherein the hydrogel One factor which determines alginate gel permeability is 
is in the form of a thin layer or disc or sheet . the mannuronic ( M ) and guluronic ( G ) acid contents of the 
In certain aspects of the invention , there is provided a 5 gel . Gels with a high M : ratio have a small intrinsic pore 
composition comprising a hydrogel wherein a population of size . The M : G ratio may be manipulated to increase the 
cells is encapsulated or entrapped within the hydrogel . In permeability of gels as necessary to improve the viability of 
some embodiments , the composition is packaged in a form encapsulated cells . High M alginates are , however , more biocompatible and clinically useful than high G alginates suitable for transportation to a remote location . 
In other aspects of the invention , there is provided a 10 which tend to form very brittle and viscous gels . In some embodiments , the G content of the alginate gel is 0-30 % . In method of treating an ocular injury in a subject , the method some embodiments , the M content is preferably 30-70 % . In comprising the steps : ( a ) providing a hydrogel comprising some preferred embodiments , the gel is an alginate gel with corneal stem cells ; ( b ) contacting the ocular injury with said a M content of 50-70 % or 60-70 % and the gel additionally hydrogel ; and optionally ( c ) securing the said hydrogel at the 15 comprises or comprised HEC . 
site of the ocular injury . In yet other embodiments of the invention , the hydrogel 
The hydrogel referred to herein comprises a hydrogel forming polymer is a cross - linked acrylic acid - based ( e.g. 
forming polymer having a cross - linked or network structure polyacrylamide ) polymer . 
or matrix ; and an interstitial liquid . The hydrogel is capable In yet further embodiments , the hydrogel - forming poly 
of suppressing or preventing cell division and / or differen- 20 mer is a cross - linkable cellulose derivative , a hydroxyl ether 
tiation in cells encapsulated or entrapped therein . Preferably , polymer ( e.g. a poloxamer ) , pectin or a natural gum . 
the hydrogel is semi - permeable . In some embodiments of the invention , the hydrogel is not 
The term " hydrogel - forming polymer ” refers to a polymer thermo - reversible at physiological temperatures , i.e. the 
which is capable of forming a cross - linked or network sol - gel transition of the hydrogel cannot be obtained at a 
structure or matrix under appropriate conditions , wherein an 25 temperature of 0-40 ° C. 
interstitial liquid and cells may be retained within such a The structure of the hydrogel may be changed by varying 
structure or matrix . The hydrogel will comprise internal the concentration of the hydrogel - forming polymer in the 
pores . hydrogel . The structure affects the viability of the cells in the 
Initiation of the formation of the cross - linked or network hydrogel , the rate of differentiation of the cells as well as 
structure or matrix may be by any suitable means , depending 30 affecting the robustness of the gel and its handling proper 
on the nature of the polymer . ties . 
The polymer will in general be a hydrophilic polymer . It Preferred concentrations of the hydrogel - forming poly 
will be capable of swelling in an aqueous liquid . In one mer in the hydrogel are 0.2-2.6 % ( weight of polymer to 
embodiment of the invention , the hydrogel - forming polymer volume of interstitial liquid ) , 0.2-0.4 % , 0.4-0.5 % , 0.5-0.7 % , 
is collagen . In this embodiment , the collagen hydrogel 35 0.7-1.1 % , 1.1-1.3 % , 1.3-2.2 % and 2.2-2.6 % . 
comprises a matrix of collagen fibrils which form a con In other embodiments , the concentration of the hydrogel 
tinuous scaffold around an interstitial liquid and the cells . forming polymer in the hydrogel is above 0.25 % , 0.3 % , 
Dissolved collagen may be induced to polymerise / aggregate 0.4 % , 0.5 % or 0.6 % . In other embodiments , the concentra 
by the addition of dilute alkali to form a gelled network of tion of the hydrogel - forming polymer in the hydrogel is 
cross - linked collagen fibrils . The gelled network of fibrils 40 below 2.4 % , 1.5 % , 1.4 % , 1.3 % or 1.2 % . In some preferred 
supports the original volume of the dissolved collagen embodiments , the concentration of the hydrogel - forming 
fibres , retaining the interstitial liquid . General methods for polymer in the hydrogel is about 0.3 % , about 0.6 % or about 
the production of such collagen gels are well known in the 1.2 % . In some particularly preferred embodiments , the con 
art ( e.g. WO2006 / 003442 , WO2007 / 060459 and WO2009 / centration of the hydrogel - forming polymer in the hydrogel 
004351 ) . 45 is about 1.2 % . In some particularly preferred embodiments 
The collagen which is used in the collagen gel may be any of the invention , the hydrogel is formed from about 1.2 % 
fibril - forming collagen . Examples of fibril - forming colla sodium alginate or from about 1.2 % strontium alginate . 
gens are Types I , II , III , V , VI , IX and XI . The gel may It is recognised that mammalian cells are of different 
comprise all one type of collagen or a mixture of different sizes . Preferably the pore size is optimised therefore for the 
types of collagen . Preferably , the gel comprises or consists 50 type of cells which are entrapped within the hydrogel . In 
of Type I collagen . In some embodiments of the invention , some embodiments of the invention , the hydrogel is 
the gel is formed exclusively or substantially from collagen obtained or obtainable using a pore size increasing agent . 
fibrils , i.e. collagen fibrils are the only or substantially the This agent may form an integral part of the hydrogel when 
only polymers in the gel . In other embodiments of the in use , or it may be completely , substantially completely or 
invention , the collagen gel may additionally comprise other 55 partially removed from the hydrogel prior to use . Preferably , 
naturally occurring polymers , e.g. silk , fibronectin , elastin , the pore size increasing agent is an agent which produces 
chitin and / or cellulose . Generally , the amounts of the non pores in the range 0.1-3.0 um , preferably 0.2-3.0 um , 0.1-1.0 
collagen naturally occurring polymers will be less than 5 % , um or 0.1-0.4 um . 
preferably less than 4 % , 3 % , 2 % or 1 % of the gel ( wt / wt ) . The internal pore dimensions of the pores within the 
Similar amounts of non - natural polymers may also be pres- 60 hydrogels may be measured by chemically dehydrating the 
ent in the gel , e.g. polylactone , polylactide , polyglycone , hydrogel , exposing the internal surfaces , coating them with 
polycaprolactone and / or phosphate glass . gold and then viewing them using a scanning electron 
In some embodiments of the invention , the hydrogel microscope . 
forming polymer is alginic acid or a alginate salt of a metal In some embodiments , the pore size increasing agent is an 
ion . Preferably , the metal is a Group 1 metal ( e.g. lithium , 65 agent which is soluble in the interstitial liquid and which 
sodium , or potassium alginate ) or a Group 2 metal ( e.g. dissolves out of the hydrogel over the encapsulation period , 
magnesium , calcium , barium or strontium alginate ) . Prefer thus leaving pores of suitable sizes . 
5 
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In some preferred embodiments , the pore size increasing The hydrogel comprises a plurality of individual cells 
agent is hydroxyethyl cellulose ( HEC ) . In this embodiment , retained therein . These cells are in general separated or 
HEC may be used in the preparation of the hydrogel ; it is dispersed within the hydrogel , i.e. the cells are not connected 
then completely , substantially completely or partially in the form of a tissue or organ . Preferably , the cells are 
removed from the hydrogel prior to use . Preferred concen primary cells . The cells are live or viable cells or substan 
trations of HEC in the hydrogel ( during preparation ) include tially all of the cells are live or viable . In some embodiments 
0.5-3.0 % HEC , more preferably 1.0-2.5 % , and even more of the invention , the cells are all of the same type . For 
preferably 1.2-2.4 % HEC . In some preferred embodiments , example , they are all brain cells , muscle cells or heart cells . 
the concentration of HEC in the hydrogel ( during prepara In other embodiments , the cells are all from the same 
tion ) is about 1.2 % or about 2.4 % . ( Concentrations are given lineage , e.g. all haematopoietic precursor cells . In some 
as weight % ) . The HEC may be suspended in the gels as embodiments , the cells are stem cells , for example , neural 
micelles . Removal of the HEC may be attained by washing stem cells or embryonic stem cells . Preferably the cells are 
the hydrogel in a suitable aqueous solvent or buffer , e.g. mammalian cells . 
tissue culture medium . In some preferred embodiments , the cells are adipocytes , 
A pore size increasing agent could be of low molecular astrocytes , blood cells , blood - derived cells , bone marrow 
weight or of a polymeric nature . An example of a low cells , bone osteosarcoma cells , brain astrocytoma cells , 
molecular weight compound could be sucrose that can be breast cancer cells , cardiac myocytes , cerebellar granule 
incorporated into a hydrogel in the form of microcrystals cells , chondrocytes , corneal cells , dermal papilla cells , 
and will dissolve over the encapsulation period . Alterna- 20 embryonal carcinoma cells , embryonic stem cells , embryo 
tively it could be any water - soluble polymer . The advantage kidney cells , endothelial cells , epithelial cells , erythroleu 
of using water - soluble polymers compared to small molecu kaemic lymphoblasts , fibroblasts , foetal cells , germinal 
lar weight compounds is their slower dissolution profile matrix cells , hepatocytes , intestinal cells , keratinocytes , 
allowing better control over the pore size . keratocytes , kidney cells , liver cells , lung cells , lympho 
In other embodiments of the invention , the pore size 25 blasts , melanocytes , mesangial cells , meningeal cells , mes 
increasing agent may be a water - soluble polymer . Examples enchymal stem cells , microglial cells , neural cells , neural 
of suitable polymers include poly ( vinylpyrrolidone ) , poly stem cells , neuroblastoma cells , oligodendrocytes , oligoden 
ethyleneglycol , a high molecular weight glucose - based droglioma cells , oral keratinocytes , organ culture cells , 
polymer ( e.g. dextran , starch , pullulan ) , and a celluosecel osteoblasts , ovarian tumour cells , pancreatic beta cells , 
lulose - based polymer ( e.g. hydroxypropylmethylcellulose , 30 pericytes , perineurial cells , root sheath cells , schwann cells , 
methylcelluose ) , methylcellulose , hydroxypropylcellulose , skeletal muscle cells , smooth muscle cells , stellate cells , 
carboxymethylcellulose ) , poly ( vinyl alcohol ) , polyacrylam synoviocytes , thyroid carcinoma cells , villous trophoblast 
ide , poly ( methyl vinyl ether ) , and block copolymers of cells , yolk sac carcinoma cells , oocytes , sperm and 
polyethylene glycol and polypropylene glycol ( e.g. Pluron embryoid bodies . In some embodiments of the invention , the 
ics ) . 35 cells are corneal cells . 
In some embodiments of the invention , the pore - size In other preferred embodiments of the invention , the cells 
increasing agent is gelatin beads . are corneal stem cells preferably comprising limbal epithe 
In some embodiments of the invention , the hydrogel still lial cells , i.e. a heterogeneous mixture of stem cells and 
comprises detectable levels of the pore - size increasing differentiated cells which is obtainable from the limbus at 
agent , e.g. a water soluble polymer . 40 the edge of the cornea . In other words , the composition 
In some embodiments of the invention , the gelling of the comprising corneal stem cells may comprise a mixture of 
hydrogel is facilitated using a compound comprising a corneal stem cells and cells that have not yet fully committed 
multivalent metal cation , e.g. using calcium chloride . In to a corneal epithelial phenotype . In other embodiments , the 
particular , calcium chloride ( e.g. 50-200 mM calcium chlo cells include stromal progenitor cells such as corneal fibro 
ride , preferably 75-120 mM calcium chloride ) may be used 45 blasts ( keratocytes ) in an differentiated or undifferentiated 
to gel alignate hydrogels . form . Preferably , these corneal fibroblasts are obtained from 
In other embodiments , of the invention , an alternative the peripheral limbus or from limbal rings which are incu 
metal chloride is used , e.g. magnesium or barium or stron bated overnight with about 0.02 % collagenase at about 37 ° 
tium chloride . Alternatively , other multivalent cations may C. In another preferred embodiment , the cells are bone 
be used , e.g. La3 + or Fe3 + . 50 marrow cells . In other embodiments , the cells are chondro 
In some embodiments of the invention , the gels ( prefer cytes . In yet other embodiments , the cells are epithelial cells . 
ably alginate gels ) additionally comprises CO2 . This may aid As used herein , the term “ suppressing or preventing cell 
cell viability after cell storage , particularly after storage division ” means that the rate of cell division within all or a 
under chilled conditions . substantial proportion of the cells contained within the 
The invention further provides a process for preparing a 55 hydrogel ( for a given temperature ) is at a lower level than 
hydrogel , comprising the step of gelling the hydrogel that of control cells which are maintained under appropriate 
forming polymer in the presence of a Group 2 metal salt tissue culture conditions at the same given temperature and 
selected from the group consisting of magnesium and stron which are not entrapped or encapsulated in a hydrogel . A 
tium salts . substantial proportion may be at least 50 % , 60 % , 70 % , 80 % , 
The interstitial liquid may be any liquid in which polymer 60 90 % or 95 % . 
may be dissolved and in which the polymer may gel . As used herein , the term “ suppressing or preventing cell 
Generally , it will be an aqueous liquid , for example an differentiation ” means that the rate of cell differentiation 
aqueous buffer or cell culture medium . The liquid may within all or a substantial proportion of the cells contained 
contain an antibiotic . Preferably , the hydrogel is sterile , i.e. within the hydrogel ( for a given temperature ) is at a lower 
aseptic . Preferably , the liquid does not contain animal- 65 level than that of control cells which are maintained under 
derived products , e.g. foetal calf serum or bovine serum appropriate tissue culture conditions at the same given 
albumin . temperature and which are not entrapped or encapsulated in 
10 
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a hydrogel . A substantial proportion may be at least 50 % , For example , the hydrogel may be enclosed within a 
60 % , 70 % , 80 % , 90 % or 95 % . water - tight or air - tight material or container , e.g. a plastic 
The cells are generally seeded into the hydrogel during container . Alternatively , the hydrogel may be contained 
the formation of the hydrogel from its constituent polymers , within a vial or cryovial or tissue culture flask , optionally 
for example , by mixing the cells with a solution of the 5 together with appropriate media ( e.g. cell culture media ) . In 
monomer prior to polymerization / aggregation or prior to other embodiments , the hydrogel may be contained within a 
cross - linking of a hydrogel - forming polymer . sealed bag , with a controlled CO2 level . 
For this reason , the hydrogel is gelled under appropriate The cells may be transported by any suitable means , e.g. 
cell - compatible conditions , i.e. conditions which are not by post or courier , which might include transportation by 
detrimental or not significantly detrimental to the viability of automotive means , e.g. by car , van , lorry , motorcycle , aero 
the cells . plane , etc. Preferably , the transportation is by post or courier . 
In some embodiments of the invention , the concentration The second location is preferably a location which is 
of cells which are present in the hydrogel is 1x103-1x10 remote from the first location , e.g. at least 1 mile , preferably 
cells / ml hydrogel solution . Generally the concentration of more than 5 miles , from the first location . 
cells is less than 5x10 % , preferably 0.1x10 $ -5x10 % cells / ml In yet a further aspect , the invention provides a method 
hydrogel , more preferably 0.5x10 $ -2.3x10 cells / ml hydro for fulfilling an order or request for cells , the method 
gel , and most preferably 1.0x10 % -2.0x10 % cells / ml hydrogel . comprising the steps : ( i ) receiving an order or request for 
Particularly preferred cell concentrations include : cells ; ( ii ) encapsulating or entrapping the desired cells in a 
up to 2.5x10 cells / ml for alginate gels maintained under 20 hydrogel ; ( iii ) dispatching the cell - containing hydrogel for 
cell culture conditions ; transportation to the location specified in the order or 
up to 1.5x10 % cells / ml for alginate gels maintained under request ; and optionally , ( iv ) transporting the cell - containing 
ambient conditions ; hydrogel to the location specified in the order or request . 
up to 1.5x10 cells / ml for an alginate gel disc maintained The order or request may be received by any suitable 
under cell culture , chilled or ambient conditions . means , e.g. via the internet , email , text - message , telephone 
In the invention , the cells are embedded in the hydrogel , or post . 
i.e. the cells are generally entrapped or encapsulated within A particularly preferred embodiment of the invention the hydrogel and not merely placed on a surface of a relates to a 0.6 % calcium alginate hydrogel comprising hydrogel . living cells . The hydrogels may be produced in any suitable size . For 30 A further particularly preferred embodiment of the inven ease of transportation , however , the hydrogels are preferably tion relates to a 1.2 % calcium alginate hydrogel comprising less than 100 mm in length , preferably less than 50 mm in living cells , wherein the hydrogel is in the form of a thin length . The thickness of the hydrogel is generally 0.1-5 mm , 
preferably 1.0-2.0 mm , more preferably about 1.5 mm . layer or thin disc . Such a hydrogel is particularly suitable for The volume of the hydrogels of the invention is preferably 35 maintaining the viability of the cells entrapped therein under 
0.2-100 ml ,more preferably 0.2-50 ml , 0.2-25 ml or 0.2-10 ambient storage conditions , preferably epithelial cells . 
ml . In some preferred embodiments , the volume of the The invention further provides a process for the prepara 
hydrogel of the invention is 0.4-5 ml , preferably 0.4-4 ml , tion of a hydrogel comprising living cells , the process 
and more preferably 0.4-3 ml . In some embodiments of the comprising the steps : ( i ) gelling a hydrogel - forming polymer 
invention , the volume may be about 420 ul or about 2 ml . 40 in the presence of living cells and a water - soluble pore size 
In some embodiments of the invention , the hydrogel is in increasing agent ; and ( ii ) dissolving all or a substantial 
the form of a thin layer or disc . The disc may for example , proportion of the pore size increasing agent out of the 
have a diameter of 5-50 mm , preferably 10-30 mm , more hydrogel 
preferably 15-25 mm , and most preferably about 19 mm . The invention further provides the use a pore size increas 
The thickness of the disc is generally 0.1-5 mm , preferably 45 ing agent in the preparation of a hydrogel . Preferably , the 
0.5-2.0 mm , more preferably about 1.0 or 1.5 mm . In some pore size increasing agent is HEC . 
embodiments , the volume of hydrogel in the disc is prefer Additionally , the invention provides a process for the 
ably 200-600 ul , preferably 300-500 ul and more preferably preparation of a hydrogel comprising living cells , the pro 
400-450 ul . cess comprising the step : ( i ) gelling a hydrogel - forming 
With regard to the discs of the invention , the preferred 50 polymer in the presence of living cells and of a metal salt 
hydrogel polymer concentration is about 1.2 % due to the selected from the group consisting of magnesium and stron 
increased structural stability provided by this concentration . tium . 
Preferably , the hydrogel ( e.g. a disc ) is an uncompressed In other embodiments , the invention provides a process 
hydrogel , i.e. it has not been subjected to an axial compress for the preparation of a hydrogel comprising living cells , the 
ing force . 55 process comprising the step : ( i ) gelling a hydrogel - forming 
In some embodiments , the hydrogels are prepared under polymer in the presence of living cells , wherein the hydrogel 
GMP ( Good Manufacturing Practice ) conditions . is gelled in the form of a thin layer or disc . 
For transportation or delivery of the cells in the hydrogel , The hydrogels may be stored during transportation or 
the hydrogel may be appropriately packaged . For example , otherwise . The hydrogels comprising living cells may be 
the hydrogel may be physically protected in order to prevent 60 stored at -80 ° C. to 45 ° C. , preferably at 4 to 45 ° C. In some 
mechanical damage to the hydrogel . It may also be wrapped , embodiments , the hydrogels are stored under cell culture 
treated or encased in order to prevent water loss . conditions ( e.g. about 37 ° C. , about 5 % CO2 and about 95 % 
During transportation and / or storage , the hydrogel com humidity ) . In some embodiments , the hydrogels of the 
prising cells may be maintained in contact with ( e.g. fully or invention are stored under chilled conditions , e.g. 4-6 ° C. , 
partially immersed in ) an appropriate media . Suitable media 65 preferably about 4 ° C. In other embodiments , the hydrogels 
include cell or tissue culture media , e.g. supplemented of the invention are stored under ambient conditions , e.g. 
DMEM media . 10-25 ° C. , preferably 18-22 ° C. In some embodiments , the 
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ambient temperature may be up to 30 ° C. , or even up to 40 ° In a further embodiment , the invention provides a method 
C. In yet other embodiments , the hydrogels of the invention of treating an ocular injury in a subject , the method com 
are stored at about 37 ° C. prising the steps : ( a ) providing a hydrogel comprising cor 
In some embodiments of the invention , the hydrogel neal stem cells ; ( b ) contacting the ocular injury with said 
comprising cells is frozen prior to storage and / or transpor- 5 hydrogel ; and optionally ( c ) securing the said hydrogel at the 
tation . This may extend the time during which the cells are site of the ocular injury . 
viable post - thawing and / or increase the usable transit - time . Ocular injuries that might be treated include those related 
Hence the hydrogel may be used in this way as a post to an insufficient stromal micro - environment to support stem cryoprotectant . For example , the temperature of the hydro cell function , such as aniridia , keratitis , neurotrophic kera gel comprising cells may be reduced to below 0 ° C. , below 10 topathy and chronic limbitis ; or related to external factors -15 ° C. or below -80 ° C. that destroy limbal stem cells such as chemical or thermal The hydrogel comprising cells may or may not be allowed 
to defrost or thaw , i.e. to increase its temperature to above injuries , Stevens - Johnson syndrome , ocular cicatricial pem 
0 ° C. during storage and / or transportation , preferably at a phigoid , contact lens wear , or extensive microbial infection . 
slow , controlled or uncontrolled rate of temperature 15 Preferably , the subject is a mammal , most preferably a 
increase . In other embodiments the hydrogels of the inven human . Suitable hydrogels have been described herein . 
tion are not chilled or frozen . The hydrogel comprising corneal stem cells preferably 
The hydrogel with living cells retained therein may be comprises limbal epithelial cells , i.e. a heterogeneous mix 
stored ( e.g. during transportation ) for up to 10 or 20 weeks . ture of stem cells and differentiated cells which is obtainable 
Preferably , the cells are stored in the hydrogel for up to 1 , 2 , 20 from the limbus at the edge of the cornea . In other words , the 
3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 weeks before being released from the hydrogel comprising corneal stem cells may comprise a 
hydrogels . More preferably , the cells are stored in the mixture of corneal stem cells and cells that have not yet fully 
hydrogel for up to 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 days before committed to a corneal epithelial phenotype . 
being released from the hydrogels . As used herein , the term " corneal " cells refers to cells 
The hydrogel referred to herein is one from which living 25 which have been obtained from an animal ( preferably mam 
cells can be released . In other words , after the preservation malian ) cornea . Preferably , the cells are obtained from the 
or storage or transport of the cells contained therein , the limbal ring of the cornea , i.e. the outer edge of the cornea 
hydrogel is capable of being dissociated thus allowing the excluding the conjunctiva , iris and central cornea . The cells 
release or removal of all or substantially all of the cells may comprise or consist of epithelial cells . The cells may 
which were previously retained therein . 30 comprise or consist of corneal stem cells , preferably limbal 
The hydrogel is dissociated under appropriate cell - com corneal epithelial stem cells . Preferably , the corneal stem 
patible conditions , i.e. conditions which are not detrimental cells are human corneal stem cells . 
or not significantly detrimental the cells . Preferably , the The cells are preferably isolated within a GMP facility or 
hydrogel is dissociated by being chemically disintegrated or surgical theatre . The cells may be obtained from the subject 
dissolved . For example , alginate gels may be disintegrated 35 to be treated , from a relative of the subject to be treated or 
in an appropriate alginate dissolving buffer ( e.g. 0.055 M from non - related donor . In some embodiments , the cells may 
sodium citrate , 0.15 M NaCl , pH 6.8 ) . be derived from a non - damaged eye from the subject to be 
Preferably , at least 50 % , 60 % or 70 % of the cells remain treated . 
viable after storage , more preferably at least 80 % , 85 % , 90 % Preferably , the cells are obtained from the same species as 
or 95 % of the cells remain viable after storage . Viability may 40 the subject . 
be assessed by Trypan blue exclusion assay or other similar The damaged ocular surface may be prepared by remov 
means . Other similar means include the MTT ( 3- ( 4,5 - dim ing diseased cells and / or tissue . This may be done using 
ethylthiazol - 2 - yl ) -2,5 - diphenyltetrazolium bromide ) assay standard surgical procedures , in order to expose the under 
and examination of cell colony formation post - extraction . lying corneal stroma . The hydrogel comprising corneal stem 
In other embodiments , the invention provides the use of 45 cells may then be placed onto or over the damaged ocular 
a hydrogel as described herein as a wound dressing . Thus in surface , e.g. onto or over the corneal stroma . The hydrogel 
a further embodiment of the invention , there is provided a may be secured in place by appropriate means , e.g. using a 
method of treating a wound or an illness caused by a wound therapeutic contact lens or inserting the hydrogel under the 
in a subject , the method comprising contacting the wound conjunctiva ( the membrane surrounding the cornea ) , e.g. by 
with a hydrogel of the invention . The invention further 50 first separating the conjunctiva from the sclera , then pulling 
provides a hydrogel of the invention for use as a wound the conjunctiva across the cornea and hydrogel gel . An 
dressing appropriate suture , e.g. a purse string suture , may be used . 
Also provided is the use of a hydrogel of the invention in The conjunctiva is now covering both the hydrogel and the 
the manufacture of a medicament for the treatment of cornea . A therapeutic contact lens might also be used to 
wounds or an illness caused by a wound . In some embodi- 55 cover the conjunctiva . Optionally , the eyelid may be sutured 
ments , the wound may be due to injury ( e.g. a burn , abrasion , closed to prevent infection and / or to maintain the position of 
laceration , or more traumatic injury such as a battlefield the hydrogel , e.g. for 1 to 14 days . 
injury ) or surgery or any other causes . In yet a further embodiment , the invention provides a 
In a further embodiment , there is provided a method of method of treating a subject having a damaged ocular 
aiding blood clotting in a subject which is bleeding , the 60 surface , the method comprising the steps : ( a ) providing a 
method comprising contacting the site of bleeding with a hydrogel comprising corneal stem cells and / or growth fac 
hydrogel of the invention . The invention further provides a tors secreted or secretable by corneal stem cells ; ( b ) option 
hydrogel of the invention for use as a blood clotting agent . ally removing diseased cells and / or tissue from the damaged 
Also provided is the use of a hydrogel of the invention in ocular surface of the subject ; ( c ) contacting the damaged 
the manufacture of a medicament for the treatment of 65 ocular surface with said hydrogel ; and ( d ) optionally secur 
bleeding . The bleeding may be from an external or internal ing the said hydrogel at the site of the damaged ocular 
surface or tissue . surface . 
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The invention further provides a method of treating a comprising : ( a ) a hydrogel - forming polymer ; and ( b ) a 
damaged ocular surface in a subject , the method comprising population of living cells . Additionally , the kit may comprise 
the steps : ( a ) providing a hydrogel comprising corneal stem one or more of the following : ( c ) an interstitial liquid ; ( d ) a 
cells and / or growth factors secreted or secretable by corneal pore - size increasing agent , preferably a water - soluble pore 
stem cells ; ( b ) optionally removing diseased cells and / or 5 size increasing agent ; ( e ) a mould for forming a gel ; ( f ) 
tissue from the damaged ocular surface of the subject ; ( c ) instructions for the preparation of a hydrogel comprising 
contacting the damaged ocular surface with said hydrogel ; living cells ; ( g ) packaging to prevent mechanical damage to and ( d ) optionally securing the said hydrogel at the site of the hydrogel ; ( h ) an address label . the damaged ocular surface . 
As the hydrogel dissolves and / or disaggregates , it will 10 In some particularly preferred embodiments of the inven tion , the hydrogel comprises 1.2 % alginate and the pore size release limbal cell derived growth factors and / or the limbal 
cells to the damaged ocular surface . Transplanted cells may increasing agent is 1.2 % HEC ; and such gels are stored at ambient temperature . either directly repopulate the damaged ocular surface or 
facilitate the recruitment of therapeutically - advantageous It has been found that the mechanical strength of the 
host cells to the wound site , thereby regenerating the dam- 15 hydrogel may be enhanced by the encapsulation of a rein 
aged ocular surface . The hydrogel will be washed away forcing structure , scaffold or mesh within the gel . It may be 
gradually via the tear duct and then excreted via the kidneys , synthetic or natural polymer . Preferably , the reinforcing 
or washed directly away from the surface of the eye by a structure , scaffold or mesh is biodegradable . The reinforcing 
clinician . Excess transplanted cells may also be removed by structure , scaffold or mesh may , for example be a polymer 
similar means after a period of weeks , e.g. 1-4 weeks . 20 comprising polylactic acid ( e.g. poly ( lactic acid - co - capro 
Any of the method of treating steps may be combined lactone ) ( PLACL ) ) , collagen or nylon . 
with any of the methods of transporting cells , methods of In yet other embodiments of the invention , the hydrogel 
preparing cells , methods of fulfilling an order , methods of prises a ylon mesh . Such a composite material has the 
suppressing or preventing cell division steps described advantage of being more robust than an alginate gel and less 
herein . 25 likely to break up during storage or transit of the gel . A 
For example , the invention provides a method of treating further benefit is that the nylon mesh may be sutured , 
an ocular injury in a subject , the method comprising the thereby allowing the gel to be held by stitches . The nylon 
steps : ( a ) encapsulating or entrapping corneal stem cells in mesh may be within the gel , partially within and partially 
a hydrogel ; ( b ) transporting the cell - containing hydrogel outside the gel or outside ( i.e. on a surface of ) the gel . The 
from a first location to second location ; ( c ) contacting the 30 nylon mesh preferably has a mesh size of 0.01-100 um . 
ocular injury with said hydrogel ; and optionally ( d ) securing Preferably , it is made of a suitable non - toxic material , which 
the said hydrogel at the site of the ocular injury . may be soluble or insoluble . 
In addition to the hydrogel , one or more other agents may In a preferred embodiment , the hydrogel is in the form of 
be applied to the eye , e.g. an antibiotic , an anti - inflammatory a disc comprising a nylon mesh . Preferably , the nylon mesh 
agent , etc. 35 is embedded within the disc . 
The invention further provides a hydrogel comprising 
corneal stem cells and / or growth factors secreted or secre BRIEF DESCRIPTION OF THE FIGURES 
table by corneal stem cells for use in therapy or for use as 
a medicament . FIG . 1. The viability of a corneal epithelial cell - line in 
The invention further provides a hydrogel comprising 40 calcium alginate gel masses is dependent on polymer con 
corneal stem cells and / or growth factors secreted or secre centration , period of encapsulation and storage condition . 
table by corneal stem cells for use in treatment of an ocular HCE cells extracted from 0.3 % , 0.6 % and 1.2 % calcium 
injury or in treatment of a damaged ocular surface . alginate gel masses maintained for 1 , 3 , 5 , 7 and / or 12 days 
The invention further provides the use of a hydrogel under cell culture ( A , D ) , ambient ( B , E ) and chilled ( C , F ) 
comprising corneal stem cells and / or growth factors secreted 45 conditions were washed and suspended in medium . Num 
or secretable by corneal stem cells in the manufacture of a bers of live and dead cells were assessed by Trypan blue 
composition or medicament for treatment of an ocular injury exclusion . Proportions of live cells were expressed as a 
or in treatment of a damaged ocular surface . percentage of total cells ( 100 % ) extracted from gels . Data 
It will be appreciated that the disclosures herein relating points represent the mean ( n = 3 ) percentage live cells 
to hydrogels apply , mutatis mutandis , to the methods of 50 extracted . * Ps0.05 indicate differences between alginate 
treating aspects of this invention . In this context , the hydro concentrations . 
gel is preferably a 0.6-2.4 % alginate gel , e.g. sodium or FIG . 2. Corneal epithelial cells extracted from calcium 
calcium or strontium alginate gel , preferably strontium alg alginate gel masses are able to adhere and assemble into 
inate gel , optionally produced using a pore increasing agent colonies . HCE cells extracted from calcium alginate gel 
( e.g. HEC ) as described herein . 55 masses maintained for 7 days under cell culture ( alginate 
Particularly advantageous results have been obtained by concentrations 0.3 % : A , 0.6 % : B , 1.2 % : C ) and 5 days 
using hydrogels in the form of a thin layer or disc or sheet . under ambient ( alginate concentrations 0.3 % : D , 0.6 % : E , 
Hydrogels in such forms are shown herein to enhance the 1.2 % : F ) and chilled ( alginate concentrations 0.3 % : G , 
viability of cells . The thin layer or disc or sheet is preferably 0.6 % : H , 1.2 % : I ) conditions were washed and suspended in 
isolated . 60 medium . Cells were cultured at 37 ° C. under 5 % CO2 and 
Preferably , the gel is in the form of a disc or thin layer . The 95 % humidity . Images of cell colonies ( 100x magnification ) 
diameter of the disc is preferably 10-50 mm . The final represent 3 individual experiments . 
volume of the gel is preferably 1-5 ml . The thickness of the FIG . 3. SEM microphotographs of calcium alginate gels . 
thin layer or disc or sheet is preferably 0.1-5 mm , e.g. about Calcium alginate gel masses ( 0.3 % : A , 0.6 % : B and 1.2 % : 
1 , 2 , 3 , 4 or 5 mm . 65 C ) were dehydrated and internal surfaces were examined 
In yet a further embodiment , the invention provides a kit using SEM . Electron micrographs ( 19000x magnification ) 
for producing a hydrogel comprising living cells , the kit represent 3 individual experiments . 
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FIG . 4. The viability of limbal epithelial cells within FIG . 11. Corneal epithelial cell viability in HEC - modified 
calcium alginate gel masses is influenced by storage condi alginate gel discs correlations with the mechanical proper 
tions . Limbal epithelial cells extracted from 0.6 % calcium ties of gels . The viability of HCE cells extracted from 
alginate gel masses maintained for 1 , 3 , 5 and 7 days under alginate or HEC - modified alginate gel discs was assessed by 
cell culture , ambient or chilled conditions were washed and 5 Trypan blue exclusion . Proportions of live cells were 
resuspended in medium . Numbers of live and dead cells expressed as a percentage of total cells ( 100 % ) initially 
were assessed by Trypan blue exclusion . Proportions of live encapsulated within gels ( highlighted in black circles ) . The 
cells were expressed as a percentage of total cells ( 100 % ) compressive moduli of gels was obtained by measuring their 
extracted from gels . Data points represent the mean ( n = 3 ) yield point with a trigger force of 0.0005 N. Data points for 
percentage live cells extracted . * Ps0.05 indicate differences 10 cell viability represent the mean ( n = 3 ) percentage live cells 
between storage conditions . extracted and data points for compressive moduli represent 10 individual measurements . FIG . 5. Limbal corneal epithelial cells extracted from 
calcium alginate gel masses are able to adhere and assemble FIG . 12. Picture of calcium alginate gel disc ( 1.2 % ) with nylon mesh inside . Alginate gel disc is approximately 20 into colonies . Limbal epithelial cells extracted from 0.6 % 15 mm in length ( A ) , and is readily transferred by forceps ( B ) . calcium alginate gel masses maintained for 5 days under cell FIG . 13. hMSC and mESC were found to be evenly 
culture ( A ) and chilled ( B ) conditions , were washed and distributed within the strontium alginate gel as shown by resuspended in medium . Cells from individual conditions propidium iodide nuclear staining . 
were cultured in supplemented medium 37 ° C. under 5 % FIG . 14. The percentage of total cell survival following 
CO2 and 95 % humidity . Images of cell colonies ( 100x 20 storage in either alginate - nylon gel discs or cryopreserva 
magnification ) represent 3 individual experiments . tion . Error bars represents standard deviation . 
FIG . 6. Calcium alginate gel masses and discs . Calcium FIG . 15. The percentage of relative cell survival following 
alginate was prepared into 0.6 % gel masses ( A , C ) and 1.2 % storage in either alginate - nylon gel discs or cryopreserva 
gel discs ( B , C ) . Gel masses were approximately 12.5 mm tion . Error bars represents standard deviation . 
in length ( A ) and 6 mm in depth ( C ) , whereas gel discs were 25 FIG . 16. Comparison between mESC and hMSC prior to 
approximately 19 mm in length ( B ) and 1.5 mm in depth ( C ) . encapsulation and following extraction from alginate gels 
Images ( 100x magnification ) represent 3 individual experi after 5 days encapsulation . mESC colonies were found 
ments . under both conditions prior to encapsulation ( A ) , and fol 
FIG . 7. Limbal epithelial cell viability is enhanced within lowing alginate gel encapsulation ( B ) . Spindle shaped 
a thin disc of calcium alginate gel . Limbal epithelial cells 30 hMSC also showed no notable differences prior to ( C ) or 
extracted from 1.2 % calcium alginate gel discs maintained following ( D ) encapsulation . 
for 1 , 3 , 5 and 7 days under cell culture , ambient or chilled FIG . 17. Cell - doubling time ( hours ) . No significant dif 
conditions , were washed and resuspended in medium . Lev ferences were seen between either hMSC or mESC prior and 
els of viable cells were measured using Trypan blue exclu following gel encapsulation . Unit of x - axis : hours . 
sion assay ( A , B ) and functional cells were assessed using 35 FIG . 18. hMSC markers detection of hMSC in optimal 
the MTT assay ( C ) . Proportions of live cells were expressed culture condition , preserved in alginate gel condition and 
as a percentage of total cells ( 100 % ) extracted from gels ( A ) . cryopreservation condition . All three of MSC markers 
Data points represent the mean ( n = 3 ) percentage live cells showed increased mRNA level after alginate and cryopreser 
extracted . * Ps0.05 indicate differences between storage vation storage . 
conditions . FIG . 19. mESC markers detection of mESC in optimal 
FIG . 8. Limbal epithelial cells extracted from calcium culture condition , preserved in alginate gel condition and 
alginate gel discs are able to adhere and assemble into cryopreservation condition . mESC extracted from alginate 
colonies . Limbal epithelial cells extracted from 1.2 % cal gel showed relatively highest value of both Oct - 3 / 4 and 
cium alginate gel discs maintained for 7 days under cell SSEA1 markers . 
culture ( A ) , ambient ( B ) and chilled ( C ) conditions , were 45 FIG . 20. Expression of mESC markers between mESC 
washed and resuspended in medium . Cells were added to encapsulated within alginate gel and cryopreserved in liquid 
supplemented medium and cultured at 37 ° C. under 5 % CO2 nitrogen by flow cytometry . mESC’s were studied immedi 
and 95 % humidity . Images of cell colonies ( 100x magnifi ately following release form a 5 day storage ( alginate or 
cation ) represent 3 individual experiments . cryopreservation ) . Cells were also studied following 10 days 
FIG . 9A - B . Corneal epithelial cell viability is enhanced 50 in standard culture media post - storage . Cryopreservation 
within calcium alginate gels modified with HEC . A : Corneal resulted in a considerable , albeit temporary loss of OCT3 / 4 
epithelial cells extracted from 2.4 % calcium alginate discs , and SSEA4 expression . No difference was seen between 
1.2 % alginate : 1.2 % HEC discs and 2.4 % alginate : 2.4 % alginate - encapsulated cells . 
HEC discs maintained for 3 days under cell culture condi FIG . 21. Total cell viability ( viable cells extracted / total 
tions , were washed and resuspended in medium . Levels of 55 number encapsulated ) following 5 days at ambient storage . 
viable cells were measured using Trypan blue exclusion Results show success across a range of cell types including 
assay . Proportions of live cells were expressed as a percent immortalised cell lines , primary cells and stem cells . 
age of total cells ( 100 % ) extracted from gels . Data points 
represent the mean ( n = 2 ) percentage live cells extracted . B : EXAMPLES 
1.2 % alginate , 1.2 % alginate : 1.2 % HEC and 1.2 % alginate : 60 
2.4 % HEC gels were similarly compared . The present invention is further defined in the following 
FIG . 10. SEM microphotographs of calcium alginate and Examples , in which parts and percentages are by weight and 
calcium alginate / HEC gels . Calcium alginate gel discs were degrees are Celsius , unless otherwise stated . It should be 
dehydrated and internal surfaces were examined using SEM . understood that these Examples , while indicating preferred 
Electron micrographs ( 19000x magnification ) represent 3 65 embodiments of the invention , are given by way of illustra 
individual experiments . The references in FIGS . 9A and 10 tion only . From the above discussion and these Examples , 
to “ 4 - HEC ” refer to HEC . one skilled in the art can ascertain the essential character 
40 
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istics of this invention , and without departing from the spirit colonies post - extraction . Images of cell colonies were 
and scope thereof , can make various changes and modifi obtained at 100x magnification . 
cations of the invention to adapt it to various usages and The Trypan blue exclusion assay was performed by 
conditions . Thus , various modifications of the invention in mixing a 10 uL cell suspension with 10 uL Trypan blue dye 
addition to those shown and described herein will be appar- 5 solution ( v / v ) , before counting live ( unstained ) and dead 
ent to those skilled in the art from the foregoing description . ( stained - blue ) cells using a haemocytometer . The MTT 
Such modifications are also intended to fall within the scope ( 3- ( 4,5 - dimethylthiazol - 2 - yl ) -2,5 - diphenyltetrazolium bro 
of the appended claims . mide ) assay was performed to assess cell metabolic activity , 
The disclosure of each reference set forth herein is incor following the manufacturer's protocols . Briefly , 12 mm 
porated herein by reference in its entirety . 10 3- ( 4,5 - dimethylthiazol - 2 - yl ) -2,5 - diphenyltetrazolium bro mide was added to a 100 uL suspension of cells and this was 
incubated for 2 h at 37 ° C. Cells were then lysed using Example 1 dimethylsulphoxide ( DMSO ) , incubated for a further 10 min 
at 37 ° C. , mixed and the absorbance of the reaction product Materials and Methods ( formazan ) was measured at 540 nm . Culture of a Human Corneal Epithelial ( HCE ) Cell - Line Scanning Electron Microscopy ( SEM ) Analysis of Calcium A human corneal epithelial ( HCE ) cell - line was cultured Alginate Structure in Dulbecco's minimal essential medium ( DMEM ) and The internal surfaces of 0.3 % , 0.6 % and 1.2 % calcium Ham's F12 medium ( DMEM / F12 , 1 : 1 ) , supplemented with alginate gels were examined by SEM . Gels were fixed in 
10 % fetal bovine serum ( FBS : Hyclone , UK ) , 0.5 % dim- 20 1.25 % ( v / v ) glutaraldehyde and post - fixed for 2 hours in 1 % ethylsulphoxide ( DMSO : Sigma - Aldrich , Poole , UK ) , 10 aqueous osmium tetroxide , washed in distilled water and 
ng / ml human epidermal growth factor ( hEGF : Sigma - Al passed through a graded ethanol series ( 50 % , 70 % , 90 % and 
drich , Poole , UK ) , 5 mg / nil insulin ( Sigma - Aldrich , Poole , 100 % ) before dehydration through critical point drying . 
UK ) , 100 IU / ml penicillin and 100 mg / ml streptomycin at Dehydrated gels were mounted on aluminium stubs and 
37 ° C. under 5 % CO2 and 95 % humidity . Cells were 25 sputter coated with gold before examination using SEM 
replenished with fresh medium every 3 days and grown to ( FEI Quanta FEG 600 , UK ) . 
70-80 % confluency . Statistical Analysis 
Isolation of Epithelial cells from the Cornea Unpaired Student's t - tests were performed using Micro 
The established bovine cornea model ( 20-21 ) was used soft Excel . Results are presented as the mean of 3 individual 
for the isolation of limbal epithelial cells . Normal bovine 30 experiments with standard error of mean and P - values0.05 
eyes were obtained from a local abattoir ( Chity whole sale considered significant . 
abattoir , Guildford , UK ) within 2 h of death , transported to Results 
the laboratory at 4 ° C. and used immediately . Corneoscleral Calcium Alginate Supports Corneal Epithelial Cell Viability 
buttons were dissected using standard eye bank techniques , in a Differential Manner Under Various Storage Conditions 
as previously described ( 22 ) . The ability of a calcium alginate gel to support viable 
Encapsulation of Epithelial Cells in Calcium Alginate Gel corneal epithelial cells was investigated to examine the 
Masses and Discs suitability of this gel scaffold for the preservation of live 
HCE and limbal epithelial cells were suspended in 0.3 % , cells intended for therapeutic purposes . Immortalised human 
0.6 % and / or 1.2 % ( w / v ) sodium alginate solutions before corneal epithelial ( HCE ) cells 5 , 7 and / or 12 days and stored 
gelling into masses and discs using 102 mM CaCl2 , as 40 under cell culture ( 37 ° C. , 5 % CO2 , 95 % humidity ) , ambient 
described previously ( 23 ) . Gel masses and discs were ( 18-22 ° C. , atmospheric CO2 and humidity levels ) and 
formed by pipetting 2 mL sodium alginate / cell solutions into chilled ( 4 ° C. , atmospheric CO , and humidity levels ) con 
102 mM CaCl2 and using chromatography paper molds ditions . 
( Whatman ) immersed in 102 mM CaCl , respectively . Cell viability was assessed by the Trypan blue exclusion 
Calcium alginate gel masses and discs were suspended in 45 assay and cell attachment and colony formation post - extrac 
supplemented DMEM / F12 medium under cell culture ( 37 ° tion . Proportions of live and dead cells measured using the 
C. , 5 % CO2 , 95 % humidity ) , ambient ( 18-22 ° C. , atmo Trypan blue exclusion assay were expressed as percentages 
spheric CO2 and humidity levels ) and chilled ( 4 ° C. , atmo of the total number of cells ( 100 % ) extracted from gels . 
spheric CO2 and humidity levels ) conditions , for 1 , 3 , 5 , 7 The viability of corneal epithelial cells within calcium 
and / or 12 days . Under cell culture storage , gels were seeded 50 alginate was influenced by polymer concentration , period of 
with 5x105 cells / 2 mL gel . Initial experiments performed encapsulation and storage condition ( FIG . 1 ) . Cell viability 
under ambient and chilled conditions using gels seeded with decreased with increased periods of encapsulation under all 
5x10 cells / 2 mL gel , demonstrated a rapid decline in cell storage conditions investigated . Similar proportions of 
viability , that was prevented by reducing cell numbers to viable cells were recovered from calcium alginate gels 
3x10 % cells / 2 mL gel ; periods of encapsulation were 55 maintained under cell culture ( 32-49 % ) and chilled ( 35 
restricted to 7 days as cells did not remain alive for longer 51 % ) conditions over 7 and days respectively ( compare 
periods of time . Gel / cell matrices were replenished with FIGS . 1A and 1C ) , but cells from cell culture storage 
fresh medium every 2 days . Loss of cells from calcium assembled into larger colonies ( FIG . 2A - 2C ) than those from 
alginate gel masses due to the extraction process was ambient ( FIG . 2D - 2F ) or chilled ( FIG . 2G - 21 ) storage . 
minimal . Gels comprising 0.3 % or 0.6 % alginate supported greater 
Cell Viability Analysis levels of viable cells than 1.2 % alginate gels under cell 
Cells were extracted from calcium alginate gel masses culture ( FIGS . 1A and 1D ) , ambient ( FIGS . 1B and 1E ) and 
and discs using alginate dissolving buffer ( 0.15 M NaCl , chilled ( FIGS . 1C and 1F ) storage . Although live cells 
0.055 M sodium citrate ) . Cells from individual conditions extracted from both 0.3 % and 0.6 % alginate gels were able 
were cultured in supplemented DMEM / F12 for approxi- 65 to adhere and assemble into colonies , cells recovered from 
mately 3 days for HCE and 2 weeks for limbal epithelial 0.6 % alginate gels ( FIG . 2B ) formed larger colonies than 
cells to monitor the ability of these cells to attach and form those from 0.3 % alginate gels ( FIG . 2A ) . This pattern of 
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growth was particularly apparent under ambient ( FIG . 2D - F ) tions . Post - extraction , however , cells from cell culture stor 
and chilled ( FIG . 2G - I ) conditions . age formed large sheets whereas those from chilled storage 
The numbers of cells recovered from 0.3 % alginate gels only assembled into small colonies ( FIG . 5 ) , possibly indi 
were consistently lower than those extracted from 0.6 % cating that live cells from chilled storage were too damaged to adhere . alginate gels under cell culture storage ( FIG . 1D ) , possibly 
due to loss of cells from the loose structure ( data not shown ) Under ambient storage , limbal epithelial cell viability was 
of 0.3 % alginate gels . The reduction in cell viability in 1.2 % very poor ; cells did not remain alive for longer than 3 days ( FIG . 4 ) . alginate gels , however , may be due to detrimental effects of 
the increased alginate concentration within this gel matrix , Example 4 : The Viability of Limbal Epithelial as a 0.6 % alginate gel retained a significantly greater Cells is Enhanced in Thin Discs of Calcium 
( Ps0.05 ) number of live cells than a 1.2 % alginate gel ( FIG . Alginate 
1D ) . Dead or apoptotic cells may have contributed to the 
reduction in cell viability and recovery , as the phagocytic The effect of gel shape ( thickness ) on recovery of live 
cells necessary for their clearance ( 24-25 ) were not incor limbal epithelial cells was examined . The gel was modified 
porated within gels . 15 from an amorphous mass ( approximately 6 mm depth and 
Taken together , these data demonstrated that a 0.6 % 12.5 mm width ) to a thin disc ( approximately 1.5 mm depth 
alginate gel mass was more suitable for maintaining viable and 19 mm width ) that presented a shorter distance ( FIG . 6 ) 
epithelial cells than gel masses containing 0.3 % and 1.2 % for movement of medium nutrients to , and waste products 
alginate , under cell culture , ambient or chilled storage from encapsulated cells . 
conditions . A 1.2 % alginate gel that formed structurally more stable 
discs than 0.3 % and 0.6 % alginate gels was used , despite the 
Example 2 : The Structure of Calcium Alginate Gels lower levels of viability achieved using this concentration of 
May Influence the Viability of Encapsulated Cells the gel ( see FIG . 1 ) , as it was hypothesised that the reduced depth of the gel would compensate for low cell viability . 
As corneal epithelial cell viability varied within different 25 Cell viability was assessed using the Trypan blue exclusion 
concentrations of calcium alginate , potential links between assay and by examining cell colony / sheet formation post extraction . To determine whether the difference in limbal the structure of this gel and its ability to support viable cells epithelial cell attachment and colony formation between cell were investigated . Calcium alginate gel masses ( 0.3 % , 0.6 % culture and chilled storage cells ( see FIG . 5 ) was due to and 1.2 % ) were chemically dehydrated and internal surfaces differences in levels of active live cells , the MTT assay was were exposed and coated with gold , before analysis of their 30 used to measure cell metabolic activity . morphology using scanning electron microscopy ( SEM ) . Limbal epithelial cell viability was enhanced in calcium 
The internal structure of calcium alginate gel masses alginate gel discs compared to calcium alginate gel masses , 
comprised of irregular pore spaces with dimensions which as ambient storage that was demonstrated previously as 
increased with decreases in alginate concentration ( FIG . 4 ) . unable to support viable cells for longer than 3 days in gel 
Pore diameters ranged from 0.2-3.0 um within a 0.3 % 35 masses ( see FIG . 4 ) , supported greater levels of viable cells 
alginate gel ( FIG . 4A ) , 0.1-1.0 um within a 0.6 % alginate gel in discs over 1-7 days than cell culture and chilled storage 
( FIG . 4B ) and 0.1-0.4 um within a 1.2 % alginate gel ( FIG . ( FIG . 7 ) . Under ambient storage , approximately 65-80 % of 
4C ) . Previous reports showed that solutes migrated at a extracted cells were alive during 1-7 days of encapsulation 
slower rate through a 3 % alginate gel with small pores than in alginate gel discs , and at least 70 + 7 % of the total number 
through a 1.5 % alginate gel with relatively larger pores ( 6 ) . 40 of encapsulated cells ( 3x10C ) in these gels remained alive 
Therefore , the greater viability of cells in 0.3 % and 0.6 % after 7 days ( FIG . 7A ) . Proportions and numbers of live cells 
alginate gels than 1.2 % gels may potentially be due to their extracted from gel discs maintained under ambient storage 
more ready access to medium nutrients moving more effi over 1 and 7 days were significantly greater ( P 0.05 ) than 
ciently through pore spaces which are larger than those those extracted from gel discs under chilled storage ( FIGS . 
within 1.2 % alginate gels . 45 7A and 7B ) . 
As observed within alginate gel masses ( see FIG . 4 ) , the Example 3 : Limbal Epithelial Cell Viability in lowest levels of viable cells were extracted from gels 
Calcium Alginate Gel Masses is Affected by maintained under cell culture conditions ( FIGS . 7A and 7B ) . 
Storage Conditions Live cells extracted from cell culture storage gel discs were , 
50 however , able to assemble into cell sheets ( FIG . 8A ) similar 
To understand the extent of corneal epithelial cell viability to live cells extracted from gel discs maintained under 
within calcium alginate gels in a potentially therapeutic ambient storage ( FIG . 8B ) . Only single cells from chilled 
context , epithelial cells isolated from the corneal limbus storage gel discs adhered ( FIG . 8C ) , and the numbers of live 
( bovine model ) were encapsulated within this gel . Cells metabolically active ( FIG . 7C ) and total live ( FIG . 7B ) cells 
were encapsulated in 0.6 % calcium alginate , as this concen- 55 from chilled storage were similar . Therefore , the inability of 
tration of the gel supported viability more robustly than gels chilled storage live cells to assemble into colonies or sheets 
containing 0.3 % or 1.2 % alginate ( see FIGS . 1 and 2 ) . Cell was not due to reduced levels of metabolically active cells . 
viability was examined over 1 , 3 , 5 , and 7 days under cell Collectively , these data demonstrated that modification of 
culture , ambient and chilled storage conditions by the Try the macro - structure of a calcium alginate gel from an 
pan blue exclusion assay and cell colony / sheet formation 60 amorphous mass to a thin disc enhanced limbal epithelial 
post - extraction . cell viability , and overcame the reduction in cell viability 
Limbal epithelial cell viability was supported most observed with increases in alginate concentration . 
robustly under chilled and cell culture conditions in 0.6 % 
alginate gel masses . After 1 , 3 , 5 and 7 day encapsulation Example 5 : Gels Modified Using HEC 
periods , 10 % , 50 % , 35 % and 5 % more live cells respectively 65 
were extracted from calcium alginate gels under chilled To improve the ability of a Ca2 + alginate hydrogel to 
conditions than from those stored under cell culture condi support viable encapsulated cells , a gel was made as 
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described above but modified through the addition of The alginate gel will be washed away gradually via the 
hydroxyethyl cellulose ( HEC ) . tear duct and then excreted via the kidneys , or washed 
A 2.4 % alginate gel containing 2.4 % HEC supported 50 % directly away from the surface of the eye by a clinician . 
greater levels of live cells than a gel containing 2.4 % Excess transplanted cells will also be removed by similar 
alginate alone ( FIG . 9A ) . Cell viability was enhanced in a means after a period of 1-4 weeks . 
1.2 % alginate : 1.2 % HEC gel compared to a 2.4 % alginate : 
2.4 % HEC gel ( FIG . 9 ) . A 1.2 % gel supported lower Example 7 : Determination of M / G Ratios of 
proportions of viable cells compared to a 1.2 % alginate : Alginate Gels 
1.2 % HEC gel ( FIG . 9B ) . 
The sizes of pore spaces correlated with cell viability Alginate solution was prepared in deionised water at a 
( FIG . 10 ) . Greater levels of viable cells were retrieved from concentration of 2.5 % ( w / v ) . Alginate solutions ( 5 cm3 
gels with large internal pores than from those with relatively aliquots ) were placed in 10 cm glass microwave tubes 
smaller internal pores ( compare 2.4 % alginate with 2.4 % ( CEM ) and subjected to microwave irradiation using a 
alginate : 2.4 % HEC and compare 2.4 % alginate : 2.4 % HEC power input of 200 W , a nominal temperature of 120 ° C. and 
with 1.2 % alginate : 1.2 % HEC ) . hold time of 5 minutes . This method was adapted from the microwave - assisted rapid hydrolysis method of Chhatbar et 
Example 6 : Use of Hydrogels as Carriers for Cell al . ( Chhatbar M. , et al . “ Microwave assisted rapid method 
Transplantation for hydrolysis of sodium alginate for M / G ratio determina tion ” . Carbohydr . Polym . 2009 ; 76 : 650-656 ) , by using a 
20 research microwave reactor ( CEM Discover LabMate ) Isolation of Limbal Stem Cells instead of a domestic microwave oven . The safety cut - off Isolation occurs within a GMP facility or surgical theatre . pressure of 200 psi was never reached . Following hydroly Tissue pieces approximately 10 mmx5 mmx1 mm in size sis , the M / G ratio was determined with reference to the containing epithelial cells ( a proportion of which will be method of Chandia et al . ( Chandia N P , et al . “ Alginic acids 
adult stem cells ) and underlying stroma from the limbus ( the 25 in Lessonia trabeculata : characterization by formic acid 
anatomical region of the eye between the white sclera and hydrolysis and FT - IR spectroscopy ” . Carbohydr . Polym . 
transparent cornea ) is surgically removed by scissors or 2001 ; 46 : 81-87 ) . Briefly , the hydrolysed solution was 
blade from either donor or contralateral eye . The epithelial adjusted to pH 2.85 ( monitored with a Mettler Toledo 
cells are dissociated from the tissue using a combination of SevenEasy pH meter S20 ) using 0.1 M HCl ( Fisher ) solution 
agitation and enzyme digestion ( enzymes include collage - 30 and the resulting precipitate , poly ( guluronic acid ) was col 
nase , dispase , trypsin / EDTA , liberase ) for a period between lected by centrifugation ( Denley BS400 ) and weighed . The 
10 mins and 2 hours at 37 ° C. in basal culture medium . After supernatant was adjusted to pH 1.0 using 0.1 M HCl solution 
this ne , the epithelial cells are separated from the rest of and the second precipitate , poly ( mannuronic acid ) was col the tissue , thereby creating a suspension of limbal epithelial lected by centrifugation and weighed . 
cells containing stem cells . The value obtained for the M / G ratio was 3.3 + 0.3 ( 77 % Encapsulation of Isolated Cells M / 23 % G ) , consistent with the manufacturer's assertion that 
The number of isolated viable cells is quantified using an this alginate has a high M content . 
automated cell counter . A known number of limbal cells 
( 1x103 to 1x10 cells / 1 mL of sodium alginate solution ) is Example 8 : Analysis of the Compressive 
encapsulated in calcium alginate gels . Gels are formed in 40 Mechanical Moduli of Calcium Alginate / HEC 
discs by the addition of calcium chloride to 0.6-2.4 % sodium Hydrogels 
alginate containing or not containing HEC using circular 
moulds with a diameter of 1-5 cm . The final volume of the Gel spheres were formed by dispensing 2 mL alginate or 
gel is 1-5 ml with a thickness of 0.1-5 mm . alginate / HEC solutions dropwise into 30 mL CaCl2 ( 100 Transplantation of Encapsulated Limbal Epithelial Cells 45 mM ) . Gelled spheres were mechanically tested at 1 , 5 , 10 , 
The damaged ocular surface is first prepared by removing 15 , 20 , 25 , 30 , 45 and 60 min to determine the time periods 
diseased cells and tissue using standard surgical procedures needed for complete gelation . Alginate and alginate / HEC 
to expose the underlying corneal stroma . A disc of calcium solutions gelled into stable gels after 10-20 min exposure to 
alginate gel containing limbal epithelial cells is placed on to 102 mM CaCl2 . Mechanical testing of gels was achieved by 
the corneal stroma and held in place by either a therapeutic 50 compressing these structures using a TA.XT.plus Texture 
contact lens or inserting under the conjunctiva ( membrane Analyser ( Stable Micro Systems , Surrey , UK ) with a 5 kg 
surrounding the cornea ) by first separating the conjunctiva load cell and a P / 1 KS flat ended stainless steel probe ( Stable 
from the sclera , then the conjunctiva is pulled across the Micro Systems , Surrey , UK ) with a 1 cm² surface area . 
cornea and alginate gel using a purse string suture . The Measurement of the force was taken , with a trigger force of 
conjunctiva is now covering both the alginate gel and the 55 0.0005 N , and the yield point of gel spheres ( point at which 
therapeutic contact lens might also cover the the gels split ) was recorded . Force was recorded as the 
conjunctiva . Finally the eyelid may be sutured closed to mechanical limit of the gels , described as comparative yield 
prevent infection and to maintain the position of the alginate force and 10 measurements of each gel sample were per 
gel . formed . The results are shown in FIG . 11 . 
Therapeutic Effect 
As the alginate gel dissolves / disaggregates it will release Example 9 : Use of Alginate Hydrogel as a Stem 
limbal cell derived growth factors and / or the limbal cells to Cell Transportation Device 
the damaged ocular surface . Transplanted cells will either 
directly repopulate the damaged ocular surface or facilitate Materials and Methods 
the recruitment of therapeutically - advantageous host cells to 65 Culture of Mouse Embryonic Stem Cells 
the wound site , thereby regenerating the damaged ocular Mouse embryonic stem cells ( mESC ) were cultured in 
surface . Dulbecco's modified eagle's medium ( DMEM ) ( Stemcell 
35 
cornea . 
60 
US 10,655,120 B2 
21 22 
technologies , U.K. ), supplemented with 10 % fetal bovine containing PI fluorescent stain to visualise cell nuclei . Sec 
serum ( FBS ) ( Stemcell technologies , U.K. ) , 0.2 % 2 - mer tions were observed by fluorescence microscopy ( Carl Zeiss 
captoethanol ( Life technologies , U.K. ) , 1 % nonessential Meditec , Germany ) . 
amino acid ( Stemcell technologies , U.K. ) , 10 ug / ml leuke Cell Viability Analysis 
mia inhibitor factor ( LIF ) ( Stemcell technologies ) , 100 5 Cells were extracted from alginate gel discs by incubation 
IU / ml penicillin and 100 mg / ml streptomycin ( Invitrogen ) , for 4 mins in alginate - dissolving buffer ( 0.15M NaCl , 
in 0.1 % gelatin ( Life technologies , U.K. ) coated T75 flasks 0.055M sodium citrate ) with gentle agitation . A Trypan blue 
( Greiner CellStar® , U.K. ) at 37 ° C. under 5 % CO2 and 95 % exclusion assay was performed by mixing a 10 uL of the 
humidity . Cells were replenished with fresh medium every resulting cell suspension with 10 uL Trypan blue dye solu 
3 days and grown to 70-80 % confluence . 10 tion ( v / v ) , before counting live ( unstained ) and dead 
Culture of Human Mesenchymal Stem Cells ( stained - blue ) cells using a haemocytometer . 
Human mesenchymal stem cells ( HMSC ) were cultured in Microscopy 
low glucose DMEM ( Life technologies , U.K. ) , supple Microscopy images were obtained with a Nikon Eclipse 
mented with 10 % FBS ( Life technologies , U.K. ) , 100 IU / ml TE200 - U ( Nikon , Japan ) colour and fluorescence camera 
penicillin and 100 mg / ml streptomycin ( Life technologies , 15 with magnification of 10x . 
U.K. ) , at 37 ° C. under 5 % CO2 and 95 % humidity . Cells mESC and hMSC Growth Rate 
were replenished with fresh medium every 3 days and grown The mESC and hMSC extracted from alginate after 5 days 
to 70-80 % confluence . storage were cultured in supplemented DMEM for approxi 
Encapsulation of Mesenchymal and Embryonic Cells in mately 9 days to monitor the ability of these cells to attach 
Strontium Alginate Gel Discs 20 and form colonies post - extraction and compare growth rate 
3x10 ( viable cells ) of hMSC were suspended in 1.2 % with cryopreserved cells . Data from individual growth 
( w / v ) sodium alginate solution with 1.2 % ( w / v ) HEC , or curves were used to calculate the doubling time via www 
3x10 % ( viable cells ) of mESC were suspended in 1.2 % ( w / v ) .doubling - time.com . 
sodium alginate solution , before gelling into discs using 102 Isolation of RNA and cDNA Synthesis 
mM SrCl2 . Gel discs were formed by pipetting 2 mL sodium 25 Total RNA was isolated using the TRI reagent ( Sigma , 
alginate / cell solutions into approximately 10 mL 102 mm Poole , U.K. ) from both mESC and hMSC cells stored either 
SrCl , and using chromatography paper molds ( Whatman ) by alginate gel encapsulation or cryopreserved in liquid 
immersed in 102 mM CaCl , respectively . Briefly , to form nitrogen for 5 days according to the manufacturer's protocol . 
gel discs , a paper ring with a 2 cm diameter opening was Total RNA was quantified spectrophotometrically ( Nano 
placed over a 3 cm diameter paper disc . A nylon mesh square 30 Drop 2000 , Thermo scientific , U.K. ) , and 1 ug RNA was 
with dimension of 1.5 cmx1.5 cm was immersed in 102 mM reverse - transcribed using Revert Aid H Minus First Strand 
SrCl , and then placed in the centre of the paper ring to avoid cDNA synthesis Kit ( Fermentas , U.K. ) , following the manu 
breakup of gel during storage . These were saturated with facturer's protocol . 
102 mM SrCl , before alginate or alginate / HEC solution ( 430 Gene Expression Analysis 
uL ) containing either hMSC's or mESC's respectively was 35 Expression levels of mouse Oct - 4 and SSEA - 1 , human 
pipetted into the space within the ring . A second 3 cm CD90 , CD73 and STRO - 1 selected genes were determined 
diameter paper disc saturated with 102 mM SrCl2 was along with mouse / human GAPDH as a reference gene . 
placed over the alginate / paper assembly . Alginate or alg Primers for all the genes were designed using sequences 
inate / HEC solutions were exposed to 102 mM SrCl , for 5 obtained from the public domain . RT - PCR was carried out in 
min to allow complete gelation . 40 triplicate with input of 10 ng cDNA per reaction using Sybr 
The subsequently formed strontium crosslinked alginate Green Dye ( QIAGEN , U.K. ) chemistry on the ABI 7900 
discs of 2 cm diameter containing cells were removed from ( Applied Biosystem , U.K. ) sequence detection system . Total 
the paper mold and suspended in supplemented DMEM reaction volume was 14 ul . Pre - incubation and initial dena 
medium within a sealed cryo vial . The gels were then stored turation of the template cDNA was performed at 95 ° C. for 
at room temperature ( 18-22 ° C. , atmospheric CO2 ) for 5 45 10 min , followed by amplification for 40 cycles with 95 ° C. 
days without medium change ( n > 9 ) . for 15 sec and 60 ° C. for 1 min . The test genes were 
Cryopreservation of mESC and hMSC normalized relative to the mean CT value of the reference 
Viable mESC and hMSC were centrifuged at 1500 rpm for genes . 
5 mins and followed resuspended in freezing medium ( 50 % Expression levels of the test genes were calculated rela 
of mESC or hMSC supplement DMEM , 40 % of fresh 50 tive to their expression in cells stored in gel . Gene expres 
DMEM and 10 % dimethyl sulfoxide ( DMSO ) ( Fisher sci sion calculations were done using standard and established 
entific , U.K. ) . Each of mESC and hMSC were equally methods to get the fold change in expression patterns . 
aliquot into cryogenic storage vials ( Fisher scientific , U.K. ) , Flow Cytometry Analysis for mESC Markers 
with final concentration of 3x10- cells per vial ( n > 6 ) . The percentage of mESC expressing lineage specific 
Cryogenic vials were transferred into Mr. Frosty ( Fisher 55 markers was determined using mouse embryonic stem cell 
scientific , U.K. ) containing of 100 ml of isopropyl alcohol multi - colour flow cytometry kit ( R & D system , U.K. ) , 
( Fisher scientific , U.K. ) and placed into -80 ° C. freezer for according to the manufacturer's protocol . In brief , mESC 
overnight to allow cells slowly frozen at 1 ° C./minute . were harvested following four different treatments . 1. Imme 
Finally , Cryogenic vials were transferred into liquid nitrogen diately after extraction from alginate gel following 5 days 
for 5 days storage . 60 storage ; 2. Immediately after defrosting following liquid 
Nuclear Staining to Analysis of Cell Distribution in HEC nitrogen storage ; 3. After 10 days in standard culture con 
Modified Strontium Alginate Gel Discs ditions ( 37 ° C. , 5 % CO2 ) following extraction from alginate 
hMSC and mESC were encapsulated in strontium alginate gels and 4. After 10 days in standard culture conditions 
( 1.2 % alginate ) or HEC - modified calcium alginate ( 1.2 % following liquid nitrogen storage followed by 10 days 
alginate / 1.2 % HEC ) gel discs . Gels were embedded in OCT 65 culturing in incubator . Following each treatment , mESC 
( Tissue Tek ) , frozen and cryosectioned . Transverse sections were washed twice by PBS in 2 % fetal bovine serum , 
of gels were mounted on glass slides with Vectorshield resuspended in 0.5 mL of fixation / permeablization buffer 
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and incubated on ice for 30 minutes . Cells were gently To validate the cells phenotype after storage within stron 
vortexed intermittently in order to maintain a single cell tium alginate gel at room temperature , a number of robust 
suspension . Cells were then centrifuged , and the cell pellet stem cell markers were examined . Quantitative PCR analy 
resuspended in 200 ul of the permeabilization / wash buffer , ses were performed on hMSC and mESC before and after 5 
at which point 10 ul of Sox2 - PE , Oct3 / 4 - APC , SSEA - 1- 5 days in storage within either alginate gel discs or cryopreser 
PerCP , SSEA - 4 - FL1 antibodies or each corresponding iso vation . Both mesenchymal and embryonic cell markers were 
type control antibody was added to the cells , and then examined respectively . The QPCR results showed no sign of 
incubated for 30-45 minutes on ice in the dark . Following decreasing levels of common hMSC and mESC stem cell 
the incubation , excess antibody was removed by washing markers ( FIG . 18 and FIG . 19 ) . Interestingly , mRNA levels the cells in 2 ml permeabilization / wash buffer ; the final cell 10 of both hMSC ( CD90 , CD73 and STRO - 1 ) and mESC 
pellet was resuspended in 400 ul of PBS for flow cytometric markers ( Oct - 4 and SSEA - 1 ) actually increased after 5 days storage both inside alginate gels and in liquid nitrogen analysis . Flow cytometry was performed using BD FAC 
SCanto II cytometer ( BD bioscience , USA ) . ( cryopreservation ) . mRNA levels of hMSC markers from cells stored inside alginate gels were very close to cells Statistical Analysis 15 stored in liquid nitrogen . Surprisingly , for mESC stored Unpaired Student's t - tests were performed using Micro inside alginate gel , both Oct - 4 and SSEA - 1 mRNA levels soft Excel . QPCR and flow cytometry results are presented were two fold higher than from cryopreserved mESC . 
as the mean of 3 individual experiments with standard error Flow cytometry was performed against four specific 
of mean and P - value 0.05 considered significant . mESC markers following either storage for 5 days ( in either 
Results 20 alginate gel or liquid nitrogen ) or 10 days incubation at 37 ° 
Cell Encapsulated Inside Aliginate Gel C. under 5 % CO2 and 95 % humidity ( of previously cryo- or 
The composite gel , comprised of an alginate gel for cell gel - stored cells ) . Following storage , expression of OCT 3/4 
encapsulation containing a nylon mesh , showed increased and SSEA4 was significantly decreased by cryo - preserva 
mechanical properties ( FIG . 12 ) . tion but following 10 days in optimal culture conditions they 
Cell density and distribution of hMSC and mESC follow- 25 increased to levels similar to those seen in the alginate 
ing encapsulation within the alginate - nylon gels were shown encapsulated cells . Interestingly the expression of each 
to be similar , both showing an even distribution throughout marker remained stable following gel encapsulation , sug 
the gel FIG . 13 . gesting cells could be used immediately following release 
The Survival Status of hMSC and mESC Inside Strontium from the gel ( FIG . 20 ) . 
Alginate Gel Discs 
To examine the suitability of a strontium alginate gel disc Example 10 : Storage of Different Cell Types 
for preservation and storage of hMSC and mESC , the 
proportion of viable cells retrieved following encapsulation A number of different cell types were stored in a 1.2 % 
and storage were investigated . alginate gel disc at ambient conditions for 5 days . The results 
After a 5 - day storage period , the proportion of live cells 35 showed high viability levels after storage across a range of 
retrieved following alginate encapsulation or cryopreserva different cell types including immortalised cell lines , pri 
tion were compared between hMSC and mESC ( FIG . 14 and mary cells lines and stem cells ( FIG . 21 ) . 
FIG . 15 ) . The number of viable hMSC retrieved from The invention claimed is : 
alginate gel discs ( 82.22 % ) was slightly higher than those 1. A packaged composition comprising : 
retrieved following cryopreservation ( 77.78 % ) ; in contrast , 40 ( a ) a 0.5 % -1.3 % calcium or strontium alginate hydrogel in 
mESC stored inside alginate gel did not maintain the same the form of a thin layer or disc , wherein the hydrogel 
level of viability ( 44.44 % ) , the number retrieved following comprises pores of 0.1-3.0 um in diameter ; 
cryopreservation was similar to hMSC ( 74 % ) ( FIG . 14 ) . ( b ) a population of living cells , the living cells being 
In terms of the proportion of relative cell survival ( i.e. not entrapped or encapsulated within the hydrogel ; and 
including cells that have been lost during the storage pro- 45 ( c ) a packaging , the packaging being a water - tight or 
cess ) the two different storage conditions for both hMSC and air - tight material suitable for transportation from a first 
mESC provided a similar level . Approximately 80 % of the location to a second location , wherein the second 
retrieved hMSC from alginate - nylon gels were viable , 5 % location is at least one mile from the first location , and 
lower than the cryopreserved hMSC . However , mESC the hydrogel is enclosed within the packaging ; 
stored inside alginate gel discs actually showed increased 50 wherein the hydrogel and the living cells entrapped or 
proportion of initial encapsulated cells ( 74 % ) than cryopre encapsulated therein are in a state of storage in the 
served mESC ( 69 % ) ( FIG . 15 ) . packaging from 1 day up to 20 weeks ; 
Survival Status of hMSC and mESC Post - Extraction wherein cell division , and optionally cell differentiation , 
To further evaluate the cells ' growth following extraction of all or a substantial proportion of the living cells 
from strontium alginate - nylon gel storage , cell - doubling 55 which are entrapped or encapsulated within the hydro 
assays were performed on the extracted hMSC and mESC . gel is suppressed or prevented . 
Post - extracted culture of both hMSC and mESC at 37 ° C. 2. A packaged composition as claimed in claim 1 , wherein 
under 5 % CO2 and 95 % humidity demonstrated that cells the hydrogel comprises detectable levels of a water - soluble 
from alginate gel discs were still capable of assembling into pore size increasing agent ; and wherein the hydrogel is 
colonies ( FIG . 16 ) . More importantly , extracted cells not 60 obtained by a process , comprising : 
only survived , but also maintained similar proliferation ( 1 ) gelling a hydrogel - forming polymer in the presence of 
rates . Cell doubling measurements clearly showed no sig living cells and a water - soluble pore size increasing 
nificant difference between untreated cultured cells and agent ; and 
those extracted from calcium alginate gel discs ( FIG . 17 ) ( ii ) dissolving a substantial proportion of the pore size 
using the same passage number and initial seeding density . 65 increasing agent out of the hydrogel ; 
Expression of Common Cell Markers Following Extraction wherein the hydrogel is formed by a calcium or strontium 
from Strontium Alginate - Nylon Gels after 5 Days Storage . alginate gel . 
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3. The packaged composition as claimed in claim 1 , 
wherein the hydrogel is a 1.1-1.3 % strontium alginate 
hydrogel . 
4. The packaged composition as claimed in claim 1 , 
wherein the hydrogel is about 0.6 % or about 1.2 % calcium 5 
or strontium alginate hydrogel . 
5. The packaged composition as claimed in claim 1 , 
wherein the hydrogel has a thickness of 0.1-5.0 mm . 
6. The packaged composition as claimed in claim 1 , 
wherein the living cells are released from the hydrogel at the 10 
second location . 
7. The packaged composition as claimed in claim 2 , 
wherein the water - soluble pore size increasing agent com 
prises hydroxyethyl cellulose ( HEC ) . 
8. The packaged composition as claimed in claim 1 , 15 
wherein the living cells remain at least 50 % viable during 
transportation from a first location to a second location at a 
temperature of up to 30 ° C. 
9. The packaged composition as claimed in claim 1 , 
wherein the state of storage in the packaging is at ambient 20 
temperature . 
10. The packaged composition as claimed in claim 1 , 
wherein the living cells remain at least 50 % viable after 3 
days storage at ambient storage conditions . 
25 * 
